Retatrutide 30mg is a next-generation injectable weight loss and diabetes drug currently in clinical development by Eli Lilly. It’s not yet approved by the FDA as of 2025, but it’s widely considered the most powerful obesity drug ever tested in clinical trials — even stronger than Mounjaro (tirzepatide).
⸻
🔬 What Is Retatrutide?
• Type: Triple hormone receptor agonist
→ Acts on GLP-1, GIP, and glucagon receptors
• Dose: 30mg is the highest dose tested in clinical trials
• Frequency: Once-weekly injection
• Brand Name: Not yet announced (in development)
⸻
⚙️ How Retatrutide Works
It targets three metabolic pathways to:
1. Suppress appetite (like GLP-1s)
2. Enhance energy expenditure (via glucagon receptor)
3. Improve blood sugar control (via GIP and GLP-1)
⸻
💥 Weight Loss Results (Clinical Trial Data)
In a major Phase 2 trial, retatrutide 30mg led to:
✅ Average weight loss: 24.2% in 48 weeks
✅ Over 58 lbs lost (on average) for people starting around 240 lbs
✅ Results that exceeded tirzepatide (Mounjaro/Zepbound)
These outcomes are unmatched by any currently approved medication.
